1 FTSE 250 stock I’d consider buying for the boom in private healthcare!

This FTSE 250 company continues to grow its top and bottom lines as it helps the NHS clear the huge backlog of cases.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

One growth market in the UK in recent years has been private healthcare insurance. A handful of FTSE companies are benefitting from this rising trend, including insurance giant Aviva. Last year, the firm reported that its health insurance sales surged 41%.

Aviva CEO Amanada Blanc said: “We’ve seen individuals looking at the NHS and saying: ‘I can afford to buy health cover, so I will do that.’ So we’ve definitely seen a take-up in individual policies. We’ve also seen small businesses take advantage of the opportunity to protect their employees.”

That’s a reference, of course, to the NHS’s massive backlog of cases. In June, the waiting list reached 7.62m, with the median waiting time for treatment at 14.3 weeks (almost double the pre-pandemic wait).

Should you invest £1,000 in Bunzl Plc right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Bunzl Plc made the list?

See the 6 stocks

The new government has called the NHS a “broken” system (though not “beaten“) following years of underinvestment. Things aren’t expected to improve anytime soon, especially with budget pressures and a rapidly rising (and ageing) population.

So the steady growth of private healthcare, which is carrying out more outsourced work for the NHS, seems almost certain. Here’s one FTSE 250 stock that offers investors direct exposure to the trend.

Booming demand

Spire Healthcare Group‘s (LSE: SPI) the second-largest provider of private healthcare in the UK. It runs 38 hospitals and over 50 clinics, medical centres and consulting rooms.

The share price is up 84% in five years, giving the firm a £903m market-cap.

Created with Highcharts 11.4.3Spire Healthcare Group Plc PriceZoom1M3M6MYTD1Y5Y10YALL28 Oct 201928 Oct 2024Zoom ▾Jan '20Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '24Jul '242020202020212021202220222023202320242024www.fool.co.uk

The company’s carrying out more work for the NHS and benefitting from both people and businesses paying to avoid long waiting lists. In 2023, revenue rose 13.4% to £1.35bn, while adjusted pre-tax profit rocketed 175% to £38.8m. Free cash flow increased 71.4% to £48m.

This strong performance continued into the first half of 2024. Spire’s revenue rose 12.7% to £762.5m, and adjusted pre-tax profit jumped 20.2% to £26.8m. Growth was boosted by the acquisition of Vita Health Group, a leading provider of mental and physical health services.

NHS revenue increased 5.2%, and the average revenue per case rose 4.7% to £3,495.

For the full year, revenue’s set to jump around 12.3% to £1.53bn. And the firm’s now fully staffed at almost all sites, which should help reduce the need for expensive agency staff. 

CEO Justin Ash said: “Spire stands ready to work with the new government to help address NHS waiting lists.”

Valuation

Looking further ahead, forecasts show steady if unspectacular growth through to 2026.

Revenue
2023£1.35bn
2024£1.53bn
2025£1.62bn
2026£1.72bn

One risk here would be a government U-turn on using the private sector to bring down NHS waiting lists. This doesn’t look likely to me, but it can’t be ruled out.

Another issue is that the stock looks expensive, trading at 26 times trailing earnings. However, analysts see profits growing much faster than revenue, resulting in a cheap forward earnings multiple of 11 for 2026.

There’s also a dividend set to grow rapidly, though the yield‘s currently tiny at just under 1%.

Pure-play stock

According to Spire, more young people than ever are opting for private health insurance. This suggests going private could become the norm for a new generation, even after NHS waiting lists are reduced.

If I wanted pureplay exposure to this theme in my portfolio and had the cash, I’d consider buying shares of Spire Healthcare.

Should you buy Bunzl Plc shares today?

Before you decide, please take a moment to review this first.

Because my colleague Mark Rogers – The Motley Fool UK’s Director of Investing – has released this special report.

It’s called ‘5 Stocks for Trying to Build Wealth After 50’.

And it’s yours, free.

Of course, the decade ahead looks hazardous. What with inflation recently hitting 40-year highs, a ‘cost of living crisis’ and threat of a new Cold War, knowing where to invest has never been trickier.

And yet, despite the UK stock market recently hitting a new all-time high, Mark and his team think many shares still trade at a substantial discount, offering savvy investors plenty of potential opportunities to strike.

That’s why now could be an ideal time to secure this valuable investment research.

Mark’s ‘Foolish’ analysts have scoured the markets low and high.

This special report reveals 5 of his favourite long-term ‘Buys’.

Please, don’t make any big decisions before seeing them.

Claim your free copy now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ben McPoland has positions in Aviva Plc. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Here’s the dividend forecast for Rolls-Royce shares as Trump rocks the markets

Rolls-Royce shares have joined in the volatility over the past week. However, with the direction being largely downwards, the dividend…

Read more »

Young Asian man drinking coffee at home and looking at his phone
Investing Articles

Dividend yields of up to 11%! Here are 3 UK passive income stocks to consider

Searching for ways to supercharge your passive income with UK dividend stocks? Here are three that have grabbed our writer's…

Read more »

Young Caucasian woman at the street withdrawing money at the ATM
Investing Articles

£10,000 invested in NatWest shares at the start of 2025 is now worth…

NatWest shares surged into 2025, but things have become a little more complicated in recent weeks. Dr James Fox explores.

Read more »

Investing For Beginners

Why the FTSE 250 could outperform the FTSE 100 for the rest of the year

Jon Smith explains why the FTSE 250 could do better than its big brother when factoring in domestic exposure and…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Tariff fears send the Lloyds share price tumbling, but the dividend yield is climbing

Just when the Lloyds Banking Group share price had been rising steadily, along comes a global upheaval to knock it…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

Here’s how a stock market crash could help an investor retire years early

A stock market crash can be alarming -- but for the well-prepared investor, it can also be an exceptional opportunity…

Read more »

Investing Articles

1 key fact to remember in this stock market correction

This writer takes a look at a FTSE 100 investment trust that is catching his eye after the recent massive…

Read more »

Investing Articles

I was wrong about the Tesla stock price!

Tesla stock's been affected more than most by ‘Liberation Day’. But our writer has other concerns about Elon Musk’s company.

Read more »